KR20220136638A - Composition for preventing or treating psoriasis comprising extract of sargassum horneri - Google Patents

Abstract

The present invention relates to a composition for preventing or treating psoriasis comprising an extract of Sargassum horneri as an active ingredient. More particularly, the present invention provides a pharmaceutical composition, a composition for external application for skin, and a health-functional food composition for preventing or treating psoriasis comprising an extract of Sargassum horneri as an active ingredient. The extract of Sargassum horneri according to the present invention has excellent anti-psoriasis activity and is derived from a natural product so that psoriasis can be prevented, treated, or palliated more safely and effectively with fewer side effects.

Description

A composition for preventing or treating psoriasis containing an extract of hoesaengnijaban as an active ingredient {COMPOSITION FOR PREVENTING OR TREATING PSORIASIS COMPRISING EXTRACT OF SARGASSUM HORNERI}

The present invention relates to a composition for preventing or treating psoriasis containing an extract of Sargassum horneri as an active ingredient.

Psoriasis is a chronic inflammatory skin disease characterized by the formation of erythematous papules and plaques covered with silver-white scales of various sizes with clear boundaries on the skin. Its histological characteristics are hyperplasia of the epithelium, and in addition, it shows various clinical features such as pus, scales, and rash.

The cause of psoriasis is still not clearly known, but factors that are presumed to be the cause include genetic factors, environmental deterioration or trigger factors, and immunological factors. It is currently known that, based on genetic factors, personal life and environmental factors act as trigger factors, and proliferation and inflammatory response of keratinocytes occur by immunological factors. Exacerbating or triggering factors for psoriasis include skin trauma, infection, cold, dry climates such as winter, dry skin, stress, and medications.

The treatment of psoriasis includes applying a drug to the diseased area or phototherapy using ultraviolet rays. As the above drugs, drugs such as corticosteroids, vitamin D derivatives, moisturizers, vitamin A synthetic derivatives, immunosuppressants cyclosporine, methotrexate, steroids, etc. are used, but strong corticosteroids If the agent is applied for too long, various side effects such as capillary dilatation, dilated striatum, and skin atrophy may appear. Cyclosporine may cause damage to kidney function and problems with blood pressure. Methotrexate may cause cirrhosis or fibrosis if used accumulated There is a problem.

Sargassum horneri is a yellowish-brown seaweed of the brown algae plant of the algae family, which is widely distributed along the coast of Korea, and has a length of about 3 to 5 m. Heotroot is in the shape of a tray, and a cylindrical stem emerges from the center and forms side branches. The leaves are long oval or line-shaped, and the edges are pinnately divided. It grows on the rocks above the upper sublittoral belt, and the tip of its body floats on the water at low tide, and is mainly used as feed or food. has not been reported

Republic of Korea Patent Publication No. 10-2009-0027387 (published on March 17, 2009)

An object of the present invention is to provide a therapeutic agent for psoriasis using an extract of a natural product having few side effects and excellent anti-psoriasis efficacy.

In order to achieve the above object, the present invention provides a pharmaceutical composition for preventing or treating psoriasis containing an extract of Sargassum horneri as an active ingredient.

The present invention provides a composition for external application for skin for preventing or improving psoriasis containing an extract of Sargassum horneri as an active ingredient.

In addition, the present invention provides a health functional food composition for preventing or improving psoriasis containing an extract of Sargassum horneri as an active ingredient.

The extract according to the present invention exhibits excellent anti-inflammatory activity by inhibiting psoriasis-related etiological factors, and has anti-psoriatic activity to suppress symptoms such as skin erythema, keratin and increase in epidermal tissue thickness due to psoriasis, preventing psoriasis , it can be used as a pharmaceutical composition for treatment or improvement, a composition for external application to the skin, and a health functional food composition.

In addition, the present invention can prevent, treat or improve psoriasis more safely with fewer side effects by using a natural product.

1 is a confirmation of the psoriasis-related etiological factors (IL-6, IL-8, TNF-α) production inhibitory efficacy of the extract according to an experimental example of the present invention.
Figure 2 is a confirmation of the signaling mechanism related to the anti-psoriasis efficacy of the extract according to another experimental example of the present invention.
Figure 3 confirms the clinical change according to the treatment of hoesaengi hat extract in a mouse model of psoriasis according to another experimental example of the present invention.
Figure 4 confirms the histological changes of the skin according to the treatment of the hoesaengi hat extract in a mouse model of psoriasis according to another experimental example of the present invention.

Hereinafter, the present invention will be described in detail.

While the present inventor was studying the anti-psoriasis efficacy with extracts derived from various marine aquatic biological resources, the present invention completed.

The present invention provides a pharmaceutical composition for preventing or treating psoriasis containing an extract of Sargassum horneri as an active ingredient.

In the present specification, " Sargassum horneri " is, as described above, a yellowish-brown seaweed of the brown algae plant Mojabanum mojaban family that is widely distributed in the coast of Korea, and is used as feed or food.

As used herein, the term "extract" refers to a substance obtained by extracting a component of a natural product regardless of an extraction method, an extraction solvent, an extracted component, or the form of an extract. It may include any material obtainable by processing or processing by the method.

The extract may be extracted according to a method commonly used in the art, for example, hot water extraction, ultrasonic extraction, filtration, reflux extraction, etc., which are performed alone or in combination of two or more methods. can be

In the present invention, the hoesaengnijaban extract may be obtained by extracting the roots, stems, leaves, outposts, or mixtures thereof of the hoesaengnijaban using water, C1 to C4 alcohol or a mixture thereof as a solvent, for example, , methanol, ethanol, propanol, butanol, or an aqueous solution thereof, etc. may be included as the solvent, preferably 60 to 80% by weight, more preferably 70% by weight of an aqueous ethanol solution, but is not limited thereto.

In the present invention, the hoesaengi hat extract can suppress the inflammatory response of the skin keratinocytes (keratinocytes).

More specifically, the extract is one or more psoriasis-related etiological factors selected from the group consisting of IL-6 (interleukin 6), IL-8 (interleukin 8), and TNF-α (tumor necrosis factor-α). By inhibiting the production of , it can exhibit anti-psoriasis efficacy.

The extract can regulate the anti-psoriasis efficacy through the signaling mechanism of AKT and NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells), also known as protein kinase B (PKB). have.

According to an experimental example of the present invention, as a result of treatment of psoriasis-induced skin keratinocytes with hTNF-α/IFN-γ extract, increased production of IL-6, IL-8, and TNF-α was decreased, and it was confirmed that the expression of p-AKT and NF-κB was suppressed.

In addition, the hoesaengi hat extract can suppress the symptoms of one or more psoriasis-like lesions selected from the group consisting of skin erythema, skin scaling, and increased epidermal tissue thickness.

According to an experimental example of the present invention, when the extract was treated in a mouse model induced with psoriasis with Imiquimod (IMQ), it was confirmed that the symptoms of psoriasis-like lesions were reduced.

In the present invention, the psoriasis may include, but is not limited to, waterdrop psoriasis, plaque psoriasis, erythrodermic psoriasis, pustular psoriasis, exfoliative psoriasis, and the like.

As used herein, "prevention" refers to any action that suppresses or delays the onset of psoriasis or at least one or more symptoms of the disease by administration of the composition according to the present invention. It may also include treating a subject in remission of the disease to prevent or prevent recurrence.

As used herein, "treatment" refers to any action that improves or advantageously changes the symptoms, such as alleviating, reducing, or eliminating at least one symptom of psoriasis or the disease by administering the composition according to the present invention.

As used herein, the term "pharmaceutical composition" refers to a composition administered for a specific purpose, and for the purpose of the present invention, is administered to prevent, treat, or prevent recurrence of at least one symptom of psoriasis or the disease.

The pharmaceutical composition according to the present invention may be prepared according to a conventional method in the pharmaceutical field. The pharmaceutical composition may be combined with an appropriate pharmaceutically acceptable carrier according to the formulation, and if necessary, excipients, diluents, dispersants, emulsifiers, buffers, stabilizers, binders, disintegrants, solvents, etc. may be prepared have. The appropriate carrier and the like do not inhibit the activity and properties of the extract according to the present invention, and may be selected differently depending on the dosage form and formulation.

The pharmaceutical composition according to the present invention can be applied in any dosage form, and more specifically, it can be used by formulating oral dosage forms, external preparations, suppositories, and parenteral dosage forms of sterile injection solutions according to conventional methods.

The solid dosage form among the oral dosage forms is in the form of tablets, pills, powders, granules, gels, capsules, etc., and at least one or more excipients, for example, starch, calcium carbonate, sucrose, lactose, sorbitol, mannitol, cellulose, It can be prepared by mixing gelatin, etc., and lubricants such as magnesium stearate and talc in addition to simple excipients may be included. In addition, the capsule formulation may further include a liquid carrier such as fatty oil in addition to the above-mentioned substances.

Among the oral dosage forms, liquid formulations include suspensions, solutions, emulsions, syrups, etc. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients, for example, wetting agents, sweeteners, fragrances, preservatives, etc. may be included. have.

The parenteral formulation may include a sterile aqueous solution, a non-aqueous solution, a suspension, an emulsion, a freeze-dried formulation, and a suppository. Non-aqueous solvents and suspending agents include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. As the base of the suppository, witepsol, macrogol, Tween 61, cacao butter, laurin fat, glycerogelatin, and the like can be used. Without being limited thereto, any suitable agent known in the art may be used.

In addition, the pharmaceutical composition according to the present invention may further add calcium or vitamins to enhance therapeutic efficacy.

In the pharmaceutical composition according to the present invention, the pharmaceutical composition may be administered in a pharmaceutically effective amount.

As used herein, the term "pharmaceutically effective amount" means an amount sufficient to treat a disease at a reasonable benefit/risk ratio applicable to medical treatment and not to cause side effects.

The effective dose level of the pharmaceutical composition may be determined according to the purpose of use, the age, sex, weight and health status of the patient, the type of disease, severity, drug activity, sensitivity to drug, administration method, administration time, administration route and excretion rate, treatment It may be determined differently depending on factors including the duration, formulation, or concurrently used drugs, and other factors well known in the medical field. For example, although not constant, generally 0.001 to 100 mg/kg, preferably 0.01 to 10 mg/kg, may be administered once to several times a day. The above dosage does not limit the scope of the present invention in any way.

The pharmaceutical composition according to the present invention may be administered to any animal capable of developing psoriasis, and the animal may include, for example, not only humans and primates, but also livestock such as cattle, pigs, horses, and dogs.

The pharmaceutical composition according to the present invention may be administered by an appropriate administration route according to the form of the formulation, and may be administered through various routes, either oral or parenteral, as long as it can reach the target tissue. The administration method is not particularly limited, and for example, oral, rectal or intravenous, muscle, skin application, respiratory inhalation, intrauterine dural or intracerebroventricular injection, etc. may be administered in a conventional manner. have.

The pharmaceutical composition according to the present invention may be used alone for the prevention or treatment of psoriasis, or may be used in combination with surgery or other drug treatment.

The present invention provides a composition for external application for skin for preventing or improving psoriasis containing an extract of Sargassum horneri as an active ingredient.

As used herein, "improvement" refers to any action that improves or advantageously changes the symptoms of psoriasis or at least one or more symptoms of the disease by the composition according to the present invention, such as alleviation, reduction, or disappearance.

The hoesaengnimojaban extract has an excellent anti-psoriasis effect, and can be used as an external composition for skin for preventing or improving psoriasis.

Corresponding features may be substituted for the above-mentioned parts.

The composition for external application for skin according to the present invention may be formulated containing a cosmetically or dermatologically acceptable medium or base. These are all formulations suitable for topical application, for example, solutions, aqueous liquids, gels, solids, kneaded dry products, pastes, emulsions obtained by dispersing the oil phase in an aqueous phase, suspensions, microemulsions, microcapsules, microgranules or ions. It may be provided in the form of vesicular dispersions in the form of (liposome) and nonionic forms, or in the form of creams, skins, lotions, powders, ointments, sprays, packs, smears, patches, or cone sticks. It can also be used in the form of a foam or in the form of an aerosol composition further containing a compressed propellant. These compositions can be prepared according to conventional methods in the art.

The composition for external application for skin includes a fatty substance, an organic solvent, a solubilizer, a thickener, a gelling agent, an emollient, an antioxidant, a suspending agent, a stabilizer, a foaming agent, a fragrance, a surfactant, water, an ionic or non-ionic emulsifier cosmetology, such as fillers, sequestering agents, chelating agents, preservatives, vitamins, blocking agents, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic actives, lipid vesicles or any other ingredient commonly used in cosmetics; It may contain adjuvants commonly used in the field of dermatology. The adjuvant may be introduced in an amount generally used in the field of cosmetics or dermatology.

In addition, the present invention provides a health functional food composition for preventing or improving psoriasis containing an extract of Sargassum horneri as an active ingredient.

The hoesaengimojaban extract has excellent anti-psoriasis efficacy, and can be used as a health functional food composition for preventing or improving psoriasis.

Corresponding features may be substituted for the above-mentioned parts.

As used herein, the term "health functional food" includes food manufactured and processed using raw materials or ingredients useful for the human body in accordance with Act No. 6727 of the Health Functional Food Act, and in addition to nutritional supply, the purpose of the present invention It refers to foods with high medical and medical effects that are processed to efficiently exhibit bioregulatory functions such as prevention of psoriasis, body defense, immunity, and recovery.

The health functional food according to the present invention may be prepared in the form of powder, granules, tablets, capsules, syrups or beverages for the purpose of preventing or improving psoriasis. There is no limitation in the form that the health functional food can take, and it can be formulated in the same manner as the pharmaceutical composition and used as a functional food or added to various foods.

The health functional food may include any food in a conventional sense. For example, beverages and various drinks, fruits and their processed foods (canned fruit, jam, etc.), fish, meat and their processed foods (ham, bacon, etc.), breads and noodles, cookies and snacks, dairy products (butter, cheese, etc.) ), etc. are possible, and may include all functional foods in a conventional sense. It may also include food used as feed for animals.

The health functional food composition according to the present invention may be prepared by further including a pharmaceutically acceptable food additive (food additive) and other suitable auxiliary ingredients commonly used in the art. Unless otherwise specified, the suitability as a food additive can be determined according to the standards and standards for the relevant item in accordance with the general rules and general test methods of the Food Additives Code approved by the Ministry of Food and Drug Safety. The items listed in the 'Food Additives Codex' include, for example, chemical compounds such as ketones, glycine, calcium citrate, nicotinic acid, and cinnamic acid; natural additives such as persimmon pigment, licorice extract, crystalline cellulose, high pigment, and guar gum; Mixed preparations, such as a sodium L-glutamate preparation, a noodle-added alkali agent, a preservative preparation, and a tar dye preparation, etc. are mentioned.

The other auxiliary ingredients include, for example, flavoring agents, natural carbohydrates, sweeteners, vitamins, electrolytes, colorants, pectic acid, alginic acid, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents, etc. may further contain. In particular, as the natural carbohydrate, monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol can be used. , as the sweetener, natural sweeteners such as taumatine and stevia extract or synthetic sweeteners such as saccharin and aspartame may be used.

The effective dose of the extract contained in the health functional food according to the present invention may be appropriately adjusted according to the purpose of its use, such as prevention or improvement of psoriasis.

The health functional food composition has the advantage that there are no side effects that may occur during long-term administration of general drugs using food as a raw material, has excellent portability, and can be taken as an adjuvant for preventing or improving psoriasis.

Hereinafter, to help the understanding of the present invention, examples will be described in detail. However, the following examples are merely illustrative of the content of the present invention, and the scope of the present invention is not limited to the following examples. The embodiments of the present invention are provided to more completely explain the present invention to those of ordinary skill in the art.

<Example 1> Preparation of hoesaengi hatban extract

The hoesaeng hatban were collected from Yangyang-gun, Gangwon-do, washed with tap water, and then stored frozen at -80°C for 1 day. The frozen samples were dried for 4 days using a freeze dryer. The dry sample was pulverized using a pulverizer to prepare a powder.

70% ethanol was added to the dry sample in powder form, and extraction was repeated 8 times with an ultrasonic extractor at room temperature for 1 hour. Each extraction was filtered using a filter paper, and the filtered extract was concentrated using a vacuum concentrator. The concentrated sample was frozen at -80°C for complete drying and then dried using a freeze dryer for 4 to 5 days. The dried extract was made in powder form and stored frozen at -80°C until used in the experiment.

<Experimental Example 1> Confirmation of toxicity in human skin keratinocytes (HaCaT keratinocytes)

Cell counting kit-8 (CCK-8; Dogindo Laboratories, Japan) reagent was used to measure cell viability. HaCaT cells were dispensed in a 96-well plate at 1×10 ⁴ cells/100 μl and when the cells were stably attached for 8 hours, 1% penicillin/streptomycin was added to DMEM medium for 16 hours. . After pre-treatment with various concentrations of the extracts of hoesaengi capricornis for 1 hour, hTNF-α and IFN-γ were treated at 10 ng/ml for 24 hours. 10 μl/well of CCK-8 reagent was added and reacted in an incubator at 37° C. for 1 hour, and then absorbance at 450 nm was measured using a microplate reader (SpectraMax M2/M2e Microplate Readers, moleculardevices, USA) equipment.

At all concentrations (5, 30, 100 μg/ml) treated with the A. serrata extract, there was no significant difference compared with the untreated group, confirming that it did not affect the cell viability. Therefore, it is considered that the extracts of hoesaengnimojaban have no cytotoxicity within the treated concentration, so the experiment was carried out using the same concentrations (5, 30, 100 μg/ml) in a later experiment.

<Experimental Example 2> Confirmation of the effect of inhibiting the generation of psoriasis-related etiological factors using human skin keratinocytes

In order to confirm the anti-psoriasis efficacy of the hoesaengnimojaban extract, the psoriasis-related etiological factors (IL-6, IL-8, TNF-α) production inhibitory efficacy was confirmed. The secretion amount of inflammation-related cytokines generated from inflammation-induced HaCaT cells was measured as follows.

Cells were aliquoted at 5×10 ⁴ cells/500 μl in a 24-well plate using DMEM medium, and after 8 hours, change to DMEM medium containing only 1% penicillin/streptomycin added, and 5% CO ₂ in an incubator for 16 hours for 18 hours. incubated during Various concentrations of the extracts of hoesaengi capri were pre-treated for 1 hour, and hTNF-α and IFN-γ were treated with 10 ng/ml and cultured for 24 hours. The secretion of TNF-α, IL-6 and IL-8 cytokines in the cell culture was measured using an ELISA kit (Max human ELISA set, Biolegend, San Diego, CA).

To this end, the culture supernatant was dispensed on a capture antibody-coated ELISA microplate and reacted at room temperature for 2 hours. After the reaction, washed and diluted biotinylated anti-mouse TNF-α, IL-6 and IL-8 detection antibodies and streptavidin-horseradish peroxidase conjugate were dispensed and reacted at room temperature for 1 hour.

After that, it was washed again with PBST, and TMB substrate solution was added, followed by dark reaction at room temperature for 30 minutes. After dispensing a stop solution to terminate the reaction, absorbance at 450 nm was measured using a microplate reader (SpectraMax M2/M2e Microplate Readers, moleculardevices, USA).

After setting the concentration of HaCaT cells to a non-toxic concentration, in order to measure the efficacy of inhibiting the generation of psoriasis-related etiological factors, HaCaT cells were artificially treated with TNF-α+IFN-γ to secrete IL-6 and IL- 8, IL-6, IL-8, and TNF secreted by HaCaT cells by inducing excessive TNF-α production, and then treating the non-toxic concentration range (5, 30, 100 μg/ml) As a result of confirming the -α production inhibitory effect through ELISA Kit assay, as shown in FIG. 1, very excellent IL-6 (A), IL-8 (B) ), TNF-α (C) production inhibitory activity was confirmed.

<Experimental Example 3> Confirmation of psoriasis inhibitory regulatory efficacy in psoriasis-induced HaCaT cells and confirmation of immune-related regulatory protein expression patterns

Through the above Experimental Example 2, it was confirmed that the excellent production inhibitory activity of IL-6, IL-8 and TNF-α extract was confirmed, and the cell signaling mechanism of anti-drying efficacy was also confirmed. Intracellular phosphorylation and nuclear transcription factor NF-κB, known to induce psoriasis, were investigated.

When HaCaT cells were dispensed at 1×10 ⁵ cells/ml and the cells were stably attached for 8 hours, they were replaced with DMEM medium supplemented with only 1% penicillin/streptomycin for 16 hours. Here, the extract was treated with the genus oleracea extract, and TNF-α and IFN-γ were treated at 10 ng/ml. After 15 and 60 minutes, respectively, the cells were collected and washed with phosphate buffered saline (PBS) three times. The total protein was a mammalian lysis buffer containing cocktail inhibitor, 1M DTT, and IM EDTA, and the protein in the nucleus was NE. Cells were lysed with -PER Nuclear and cytoplasmic Extraction reagents (THERMO SCIENTIFIC, IL) to obtain proteins.

Protein Assay Dye Reagent Concentrate (Bio-Rad) was used to quantify protein, and 30 μg of lysate was separated by 10% SDS-PAGE. The electrophoresed gel was transferred to a 0.45 μm nitrocellulose membrane (MERCK) for 1 hour, and then in tris-buffered saline (TBS, pH 7.5) containing 5% skim milk, 0.1% Tween 20 solution at room temperature for 2 hours. blocking while

To examine the expression levels of phosphorylated AKT, JNK, ERK, p38 and AKT, JNK, ERK, p38, P65, and actin, p-AKT, p-AKT, p-JNK, JNK, p-ERK, ERK, p- p38 and p38 (Cell Signaling Technology Inc., USA), P65 (Thermo Fisher Scientific), and actin (BD) antibodies were diluted 1:1000 and reacted at 4C for 16 hours, followed by Tris-Buffered Saline, 0.1% Tween 20 (TBST) , pH 7.5) was washed three times. As a secondary antibody, horseradish peroxidase-conjugated anti-mouse IgG and anti-rabbit IgG were diluted 1:2,000 and reacted at room temperature for 1 hour, washed 3 times with TBST, reacted with ECL substrate for 1 to 3 minutes, and then each protein Bands were visualized using an AI600 (GE Healthcare Bio-Sciences Corp., Marlborough, MA, USA).

As a result of examining MAPKs and AKT, which are representative signaling mechanisms related to inflammation, the MAPKs signaling mechanism was not related to the inhibitory efficacy, but as shown in FIG. 2 , it was confirmed that only the AKT signaling mechanism was a cell signaling mechanism related to the inhibitory efficacy. In addition, it was confirmed that the nuclear transcription factor, NF-κB activity was significantly inhibited. It was confirmed that the anti-psoriasis efficacy of the extracts of hoesaengi capricornis was regulated through AKT and NF-κB signaling mechanisms.

<Experimental Example 4> Confirmation of clinical changes in psoriasis mouse model

A mouse model of psoriasis was established using Imiquimod (IMQ). 15 male Balb/c mice of about 6 to 8 weeks of age were purchased from Orient Bio (Seongnam, Korea), and after removing the dorsal hair using an epilator, 5% (62.5 mg/mouse) imiquimod cream (Aldara) Creamⓡ, Dong-A ST, Seoul, Korea) and 4 and 8 hours after IMQ application, 2.5μg/mouse calcipotriol (calcipotriol, CAL, psoriasis treatment substance), 0.5 mg/mouse was applied twice a day for 7 days. On the 8th day, clinical changes in psoriasis such as erythema, keratin, and skin thickening were visually observed, and skin tissues were collected.

For visual evaluation, the Psoriasis Area Severity Index (PASI), a clinical visual evaluation method used in atopic dermatitis, was used (Olivry et al. 2007). PASI was designed as a widely used method to measure the severity of symptoms of atopic dermatitis in clinical practice. In this experimental example, as shown in the table of FIG. 3, it was divided into three fields of erythema, Scaling, and Thickness, and divided into stages 0 to 4, respectively. Each item was scored as no symptoms (0 points), weak (1 points), moderate (2 points), severe (3 points), and very severe (4 points), and then evaluated.

As a result of inducing psoriatic skin inflammation on the back skin of BALB/c mice by topically applying IMQ (62.5 mg/mouse) for 7 consecutive days, as shown in FIG. 3 , compared with normal control mice, IMQ application The symptoms of the induced psoriasis-like lesion were evident. It was confirmed that significant psoriatic lesions were suppressed in the CAL (calcipotriol, 2.5 μg/mouse) treatment group, a known psoriasis treatment group, compared to the IMQ treatment group. In the experimental group, each of which was applied 500 μg of the extracts of hoesaengi capricornis, a distinct inhibitory effect on lesions was confirmed compared to the IMQ-treated group.

<Experimental Example 5> Confirmation of histological changes of skin in psoriasis mouse model

Skin tissue staining was performed with H&E stain (Hematoxylin & Eosin, Sigma-Aldrich Co.). About 5 × 5 mm of skin tissue was extracted, fixed with 4% paraformaldehyde (paraformaldehyde, pH 7.4, Sigma-Aldrich Co.), and paraffin blocks were prepared through a series of procedures, and then cut to a thickness of 5 μm. The trimmed tissue sections were deparaffinized and hydroused, stained with H&E, and confirmed with a digital slide scanner (NanoZoomer 2.0-RS; Hamamatsu, Shizuoka, Japan).

After inducing psoriasis skin inflammation on the back skin of BALB/c mice, as a result of comparison with normal control mice, as shown in FIG. 4 , the thickness of the epidermis, a symptom of psoriasis-like lesions induced by IMQ application, was normal in mice. (CTRL), the thickness was clearly thicker. In the CAL (calcipotriol, 2.5 μg/mouse) treatment group, which is a known psoriasis treatment group, it was confirmed that the thickness of the epidermis was significantly reduced compared to the IMQ treatment group. It was confirmed that in the experimental group, in which 500 μg of each 500 μg of the extract was applied to the back of the mouse to which IMQ was applied, not only the entire skin layer but also the thickness of the epidermis was significantly thinner than that of the IMQ-treated group.

As described above in detail a specific part of the content of the present invention, for those of ordinary skill in the art, it is clear that this specific description is only a preferred embodiment, and the scope of the present invention is not limited thereby. do. That is, the substantial scope of the present invention is defined by the appended claims and their equivalents.

Claims (9)

A pharmaceutical composition for preventing or treating psoriasis containing an extract as an active ingredient. The method of claim 1,
The extract is
A pharmaceutical composition for preventing or treating psoriasis, characterized in that it is extracted using water, C1 to C4 alcohol or a mixture thereof as an extraction solvent. The method of claim 1,
The extract is
A pharmaceutical composition for preventing or treating psoriasis, characterized in that it inhibits the inflammatory response of keratinocytes. The method of claim 1,
The extract is
A pharmaceutical composition for preventing or treating psoriasis, characterized in that it modulates anti-psoriasis efficacy through AKT and NF-κB signaling mechanisms. The method of claim 1,
The extract is
A pharmaceutical composition for preventing or treating psoriasis, characterized in that it suppresses the symptoms of one or more psoriasis-like lesions selected from the group consisting of skin erythema, skin scaling, and increased epidermal tissue thickness. The method of claim 1,
The psoriasis is
A pharmaceutical composition for preventing or treating psoriasis, characterized in that at least one selected from the group consisting of waterdrop psoriasis, plaque psoriasis, erythrodermic psoriasis, pustular psoriasis and exfoliative psoriasis. A composition for external application for the prevention or improvement of psoriasis, comprising an extract of Sargassum horneri as an active ingredient. 8. The method of claim 7,
The composition is
An external composition for preventing or improving psoriasis, characterized in that it is any one selected from the group consisting of aqueous solutions, gels, ointments, creams, lotions, pastes, smears and patches. A health functional food composition for preventing or improving psoriasis containing an extract of Sargassum horneri as an active ingredient.

Images